PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-32.96%
Both companies show declining cash positions (-32.96% vs CRVO's -39.29%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-32.96%
Cash + STI yoy 0.75-0.9x CRVO's -39.29%. Bill Ackman would wonder if competitor is building liquidity more aggressively.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.20%
≥ 1.5x CRVO's -14.20%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-7.82%
Below half CRVO's 503.15%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
305.95%
≥ 1.5x CRVO's 3.14%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-28.88%
≥ 1.5x CRVO's -6.71%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-28.35%
Less than half of CRVO's 86.32%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.97%
50-75% of CRVO's -48.79%. Bruce Berkowitz notes a more controlled liability line.
-23.54%
50-75% of CRVO's -42.91%. Bruce Berkowitz notes the firm keeps current liabilities growth relatively low.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.54%
50-75% of CRVO's -40.97%. Bruce Berkowitz notes a lower yoy liability increase.
2.39%
Less than half of CRVO's 18.88%. David Dodd sees fewer share issuances vs. competitor.
-4.88%
Below half CRVO's 22.95%. Michael Burry suspects major net losses or high dividends vs. competitor.
-7.49%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-31.10%
Below half CRVO's 106.11%. Michael Burry sees potential underperformance in building shareholder capital.
-28.88%
≥ 1.5x CRVO's -6.71%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.96%
50-75% of CRVO's 49.06%. Bruce Berkowitz notes comparatively lower net debt expansion.